INT298739

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.20
First Reported 2010
Last Reported 2010
Negated 4
Speculated 0
Reported most in Body
Documents 3
Total Number 10
Disease Relevance 1.58
Pain Relevance 0.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

vesicle-mediated transport (USE1) endoplasmic reticulum (USE1) lysosome (USE1)
USE1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 27 78.92 Quite High
Pain 1 27.00 Quite Low
corticosteroid 13 24.16 Low Low
palliative 8 5.00 Very Low Very Low Very Low
cytokine 2 5.00 Very Low Very Low Very Low
withdrawal 2 5.00 Very Low Very Low Very Low
depression 2 5.00 Very Low Very Low Very Low
agonist 2 5.00 Very Low Very Low Very Low
headache 2 5.00 Very Low Very Low Very Low
anticonvulsant 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Nicotine Addiction 4 100.00 Very High Very High Very High
Bronchitis 10 95.80 Very High Very High Very High
Disease 109 95.18 Very High Very High Very High
Airway Obstruction 2 94.72 High High
Pulmonary Disease 73 93.82 High High
Adverse Drug Reaction 33 91.40 High High
Weight Loss 8 84.68 Quite High
INFLAMMATION 28 78.92 Quite High
Attention Deficit Hyperactivity Disorder 1 77.56 Quite High
Pneumonia 3 68.32 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In Hungary there is neither regulation nor implementation of 'compassionate use' programmes.
Neg (neither) Regulation (regulation) of use
1) Confidence 0.20 Published 2010 Journal Trials Section Body Doc Link PMC2997627 Disease Relevance 0.07 Pain Relevance 0
The European Clinical Research Infrastructures Network (ECRIN) conducted a comprehensive survey on clinical research regulatory requirements, including questions on regulations of 'compassionate use' programmes.
Regulation (regulations) of use
2) Confidence 0.12 Published 2010 Journal Trials Section Abstract Doc Link PMC2997627 Disease Relevance 0.09 Pain Relevance 0
We found significant differences in the national regulations for 'compassionate use' programmes.
Regulation (regulations) of use
3) Confidence 0.12 Published 2010 Journal Trials Section Body Doc Link PMC2997627 Disease Relevance 0 Pain Relevance 0
In Austria, national regulations for 'compassionate use' for groups of patients, in accordance with the European Regulation 2004/726/EC, are currently under preparation.
Regulation (regulations) of use
4) Confidence 0.12 Published 2010 Journal Trials Section Body Doc Link PMC2997627 Disease Relevance 0 Pain Relevance 0
In Italy, the 'compassionate use' of a medicinal product used in non-authorised conditions in a single patient in exceptional circumstances is allowed and is regulated by the Ministry of Health Decree May 8, 2003 and by the Legislative Decree April 24, 2006 n. 219 [15,16].
Regulation (regulated) of use
5) Confidence 0.12 Published 2010 Journal Trials Section Body Doc Link PMC2997627 Disease Relevance 0 Pain Relevance 0
In Sweden, there is no system regulating 'compassionate use' programmes.
Neg (no) Regulation (regulating) of use
6) Confidence 0.12 Published 2010 Journal Trials Section Body Doc Link PMC2997627 Disease Relevance 0.09 Pain Relevance 0
In order to understand how 'compassionate use' programmes are regulated, and to ascertain if the desired common approach is being achieved in Europe, ECRIN surveyed ten European countries representing approximately 70% of the EU population [6].
Regulation (regulated) of use
7) Confidence 0.12 Published 2010 Journal Trials Section Body Doc Link PMC2997627 Disease Relevance 0.05 Pain Relevance 0
In Ireland, currently there is no system regulating 'compassionate use' programmes, however, 'compassionate use' programmes can fall under the Irish clinical trial regulations SI 190 of 2004 or SI 540 of 2007 [13].
Neg (no) Regulation (regulating) of use
8) Confidence 0.12 Published 2010 Journal Trials Section Body Doc Link PMC2997627 Disease Relevance 0.06 Pain Relevance 0
To summarize, COPD patients with more severe airway obstruction, GOLD stage IV disease, those with chronic bronchitis, and those who had at least one exacerbation in the previous year, experienced improvement in pre- and postbronchodilator FEV1 and a reduction in moderate and severe exacerbations, and these improvements were independent of smoking status or LABA use.65

EOS and HELIOS

Neg (independent) Regulation (independent) of use associated with nicotine addiction, pulmonary disease, airway obstruction, bronchitis and disease
9) Confidence 0.03 Published 2010 Journal Drug Des Devel Ther Section Body Doc Link PMC2915539 Disease Relevance 1.08 Pain Relevance 0.04
The Royal Brompton & Harefield NHS Trust, as sponsor of this study, has responsibility to ensure arrangements are in place to record, notify, assess, report, analyse and manage adverse events in order to comply with the UK regulations of Medicines for Human Use (Clinical Trials) Regulations 2004.
Regulation (regulations) of Use
10) Confidence 0.00 Published 2010 Journal BMC Pediatr Section Body Doc Link PMC2830203 Disease Relevance 0.14 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox